Skip to content
LATEST
Health

AbbVie’s Bimatoprost SR glaucoma trial posts Phase 3 results

The completed registry entry concerns duration of effect in open-angle glaucoma or ocular hypertension, not a disclosed efficacy comparison.

AbbVie's Bimatoprost SR glaucoma trial posts Phase 3 results

AbbVie's Phase 3 Bimatoprost SR trial in open-angle glaucoma or ocular hypertension was listed as completed with results on ClinicalTrials.gov on Nov. 13, 2026.

The update matters because Phase 3 trials are late-stage human studies often used to support regulatory decisions; this registry notice identifies completion and posting status rather than a published efficacy conclusion.

ClinicalTrials.gov identifies the study as NCT03850782 and names AbbVie as sponsor. The trial evaluated the duration of effect of Bimatoprost SR in participants with open-angle glaucoma or ocular hypertension.

Open-angle glaucoma and ocular hypertension are eye conditions linked to pressure-related risk to vision. A sustained-release glaucoma treatment is designed to maintain drug exposure over time, making duration of effect a central clinical question.

Completion of the trial does not by itself show how long Bimatoprost SR worked, how it compared with any comparator, or what adverse events occurred. Those questions require review of the posted outcome and safety data, and any later regulatory or peer-reviewed disclosures.

Source: clinical registry, ClinicalTrials.gov, Nov. 13, 2026

Atlas360 reports health research and does not provide medical advice.

More stories

Latest news